Literature DB >> 29121263

High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data.

Katinka Albrecht1, Andres Luque Ramos2, Falk Hoffmann2, Imke Redeker1, Angela Zink1,3.   

Abstract

Objectives: To investigate the prevalence of diabetes in patients with RA and the impact of diabetes on self-reported outcomes and health care.
Methods: RA patients between the ages of 18 and 79 years were randomly selected from a nationwide statutory health insurance fund and were surveyed about rheumatological care and disease burden. Comorbid diabetes (E10-14) was analysed regarding age, sex, BMI and socioeconomic status. Disease burden, comorbidity and prescriptions were compared in RA patients with and without diabetes. Predictors of rheumatological care were identified by multivariate regression.
Results: Of the 2535 RA patients, 498 (20%) had diabetes. Diabetes was more frequent in males, in older patients, in patients with a higher BMI and in those with a lower socioeconomic status. All disease outcomes were poorer in RA-diabetes patients and were mainly attributable to a higher BMI. RA-diabetes patients received less DMARDs (40% vs 48%) and had more hospital stays (41% vs 30%) than patients without diabetes (all P < 0.05). Rates of cardiovascular disease (35% vs 15%), depression (39% vs 26%) and renal failure (23% vs 8%) were higher in RA-diabetes patients (all P < 0.0001). They were less frequently treated by rheumatology specialists: 57% vs 67%; odds ratio = 0.64 (95% CI: 0.45, 0.92), after controlling for confounders.
Conclusion: The prevalence of diabetes in patients with RA is high and is associated with known sociodemographic factors. More than 40% of patients with RA and diabetes were not under rheumatological care even though they reported a high disease burden, were frequently hospitalized and often presented with further comorbidities.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  comorbidities; diabetes; health care; rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 29121263     DOI: 10.1093/rheumatology/kex414

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  11 in total

Review 1.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 2.  Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.

Authors:  Marco Infante; Nathalia Padilla; Rodolfo Alejandro; Massimiliano Caprio; David Della-Morte; Andrea Fabbri; Camillo Ricordi
Journal:  Medicina (Kaunas)       Date:  2022-04-21       Impact factor: 2.948

3.  Comment on: Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine.

Authors:  Anil Pareek; Ravi Tejraj Mehta; Shruti Dharmadhikari; Kumar Naidu
Journal:  Rheumatol Adv Pract       Date:  2019-10-18

4.  Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.

Authors:  Mark C Genovese; Gerd R Burmester; Owen Hagino; Karthinathan Thangavelu; Melitza Iglesias-Rodriguez; Gregory St John; Miguel A González-Gay; Thomas Mandrup-Poulsen; Roy Fleischmann
Journal:  Arthritis Res Ther       Date:  2020-09-09       Impact factor: 5.156

Review 5.  Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.

Authors:  Sakir Ahmed; Armen Yuri Gasparyan; Olena Zimba
Journal:  Rheumatol Int       Date:  2021-01-03       Impact factor: 3.580

6.  The impact of diabetes mellitus on treatment and outcomes of rheumatoid arthritis at 5-year follow-up: results from a multi-ethnic Asian cohort.

Authors:  Chuanhui Xu; Mei Yun Yong; Ee Tzun Koh; Rinkoo Dalan; Khai Pang Leong
Journal:  Rheumatol Adv Pract       Date:  2021-11-04

7.  Family History of Rheumatic, Autoimmune, and Nonautoimmune Diseases and Risk of Rheumatoid Arthritis.

Authors:  Vanessa L Kronzer; Cynthia S Crowson; Jeffrey A Sparks; Elena Myasoedova; John Davis
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-02       Impact factor: 4.794

8.  Scoring Model to Predict a Low Disease Activity in Elderly Rheumatoid Arthritis Patients Initially Treated with Biological Disease-modifying Antirheumatic Drugs.

Authors:  Takahiro Okada; Noriko Kohyama; Miki Takenaka; Takashi Yamaguchi; Tatsuya Kurihara; Kosuke Sakurai; Yusuke Miwa; Mari Kogo
Journal:  Intern Med       Date:  2021-06-15       Impact factor: 1.271

Review 9.  Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis.

Authors:  Ennio G Favalli
Journal:  Rheumatol Ther       Date:  2020-07-30

10.  Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit.

Authors:  Anne Grete Semb; Silvia Rollefstad; Eirik Ikdahl; Grunde Wibetoe; Joseph Sexton; Cindy Crowson; Piet van Riel; George Kitas; Ian Graham; Solbritt Rantapää-Dahlqvist; George Athanasios Karpouzas; Elena Myasoedova; Miguel A Gonzalez-Gay; Petros P Sfikakis; Maria G Tektonidou; Argyro Lazarini; Dimitrios Vassilopoulos; Bindee Kuriya; Carol Hitchon; Maria Simona Stoenoiu; Patrick Durez; Virginia Pascual-Ramos; Dionicio Angel Galarza-Delgado; Pompilio Faggiano; Durga Prasanna Misra; Andrew A Borg; Rong Mu; Erkin M Mirrakhimov; Diane Gheta; Karen Douglas; Vikas Agarwal; Svetlana Myasoedova; Lev Krougly; Tatiana Valentinovna Popkova; Alena Tuchyňová; Michal Tomcik; Michal Vrablik; Jiri Lastuvka; Pavel Horak; Helena Kaspar Medkova; Anne M Kerola
Journal:  RMD Open       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.